When was Spark Therapeutics founded?

Spark Therapeutics was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Spark Therapeutics located?

Spark Therapeutics is headquartered in Philadelphia, United States.

Who is the current CEO of Spark Therapeutics?

Jeffrey Marrazzo of Spark Therapeutics.

How many employees does Spark Therapeutics have?

As of May 22, 2025, the latest employee count at Spark Therapeutics is 826.

Is Spark Therapeutics a funded company?

Spark Therapeutics is a funded company, having raised a total of $82.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 22, 2013.

How much is Spark Therapeutics worth?

The last known valuation of Spark Therapeutics was $***** as of Feb 22, 2019.

When was the latest funding round of Spark Therapeutics?

Spark Therapeutics' latest funding was a $***** Series B round on May 23, 2014, with participation from 6 investors.

What is the annual revenue of Spark Therapeutics?

Annual revenue of Spark Therapeutics is between $50M and $100M as on Dec 31, 2018

Where does Spark Therapeutics rank among its competitors?

Spark Therapeutics ranks 4th amongst 780 active competitors, of which 264 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in Aug, 2025.

Who are the top competitors of Spark Therapeutics?

Spark Therapeutics' top competitors include Alnylam, BridgeBio and Alexion. Among them, Strand Therapeutics secured the most recent funding round in August, 2025.

Spark Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Spark Therapeutics an acquired company?

Spark Therapeutics got acquired by Roche on Feb 22, 2019.

Company Details

Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.

Website: sparktx.com
Social

Key Metrics

Founded Year

2013

Location

Philadelphia, United States

Stage

Acquired

Total Funding

$82.8M in 2 rounds

Latest Funding Round

Series B, May 23, 2014, $*****

Last Known Valuation

$***** as on Feb 22, 2019

Investors

Sofinnova Investments & 7 more

Ranked

4^th among 780 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2018

Employee Count

826 as on May 22, 2025

Investment & Acquisitions

CombiGene & 1 more

Similar Companies

Alnylam & 964 more

Exit Details

Acquired by Roche (Feb 22, 2019)

View Spark Therapeutics' full profile

Spark Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Spark Therapeutics, Inc. CIN: 1609351 , United States, Active	Mar 12, 2013	$50M - $100M (As on Dec 31, 2018)	822 (As on Dec 31, 2021)	-

Spark Therapeutics got acquired by Roche on Feb 22, 2019 at an acquisition amount of $*****.

Click here to take a look at Spark Therapeutics's acquisition in detail

Spark Therapeutics has raised a total funding of $82.8M over 2 rounds. Its first funding round was on Oct 22, 2013. Its latest funding round was a Series B round on May 23, 2014 for $*****. 6 investors participated in its latest round. Spark Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Spark Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 23, 2014	1868053	Series B	8284845	5524749	5475936	9319998
Oct 22, 2013	9609346	Series A	9169874	4881317	1537136	Children's Hospital of Philadelphia

Access funding benchmarks and valuations. Sign up today!

View details of Spark Therapeutics's funding rounds and investors

The founders of Spark Therapeutics are Katherine High, Fraser Wright and Jeffrey Marrazzo.

Here are the details of Spark Therapeutics' key team members:

Katherine High: Co-Founder & CSO, MD of Spark Therapeutics. They are also an angel investor in 1 startup.
Fraser Wright: Co-Founder and Chief Technology Advisor / Officer of Spark Therapeutics.
Jeffrey Marrazzo: Co-Founder & CEO of Spark Therapeutics.

View details of Spark Therapeutics's Founder profiles and Board Members

Spark Therapeutics' employee count trend

Spark Therapeutics has 826 employees as of May 25. Here is Spark Therapeutics's employee count trend over the years:

Employee count trend for Spark Therapeutics

Uncover Spark Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spark Therapeutics include Alnylam, BridgeBio and Alexion. Here is the list of Top 10 competitors of Spark Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Allen & Company & 9 others	79/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Wellington, Brookside Capital & 6 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	71/100
7th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
9th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
10th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Spark Therapeutics's competitors? Click here to see the top ones

Spark Therapeutics has made 1 investment in CombiGene and acquired Genable Technologies.

Media has covered Spark Therapeutics for a total of 6 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.